1 / 10Brokerage firm Prabhudas Lilladher has unveiled nine stock ideas for Samvat 2082, a mix of large, mid and small caps. PL expects steady returns from largecaps and strong growth from select mid and smallcaps.
2 / 10Apollo Hospitals Enterprise | The brokerage has a price target of ₹9,300, implies a potential upside of 21%. India’s largest omni-channel healthcare provider is expanding 3,600 beds and unlocking value through its Apollo HealthCo demerger. PL expects 26% EBITDA CAGR over FY25-28 driven by scale and digital reach.
3 / 10Britannia Industries | The brokerage has a price target of ₹6,484, implies a potential upside of 10%. The FMCG major remains a high-conviction pick with GST cuts expected to lift volumes by 6-8%. PL sees margin stability and 16.9% EPS growth aided by innovation and premiumisation.
4 / 10Hindustan Aeronautics (HAL) | The brokerage has a price target of ₹5,500, implies a potential upside of 16%. Armed with an order book of ₹2.5 lakh crore, HAL is set for a decade of strong execution, led by Tejas Mk1A and LCH Prachand orders. PL projects revenue CAGR of 11.6% over FY25-27.
5 / 10ICICI Bank | The brokerage has a price target of ₹1,730, implies a potential upside of 25%. The top-performing private bank continues to impress with high-quality earnings and strong capital ratios. PL expects RoA of 2.2% and RoE of 15.5% by FY27.
6 / 10ITC Ltd. | The brokerage has a price target of ₹530, implies a potential upside of 33%. After a year of margin pressure, PL expects a turnaround driven by softer leaf tobacco prices, FMCG recovery and GST 2.0 on cigarettes. ITC trades at 19.8x FY28 PE with 4% dividend yield.
7 / 10State Bank of India (SBI) | The brokerage has a price target of ₹960, implies a potential upside of 9%. SBI remains PL’s top PSU bet, supported by strong credit growth, ₹25,000 crore capital raise and superior provisioning. Core earnings expected to grow 22% YoY in FY27.
8 / 10DOMS Industries | The brokerage has a price target of ₹3,085, implies a potential upside of 22%. GST cuts on key stationery products and new greenfield expansion in Umbergaon to drive growth. PL sees sales/PAT CAGR of 24% over FY25–27, keeping it a high-conviction smallcap.
9 / 10Eris Lifesciences | The brokerage has a price target of ₹1,975, implies a potential upside of 23%. The pharma player’s acquisitions strengthen its derma and injectable portfolio. PL expects margin expansion beyond 35% and steady revenue growth through FY27.
10 / 10KEI Industries | The brokerage has a price target of ₹4,946, implies a potential upside of 15%. Riding strong cable demand, export growth and capacity expansion, PL expects revenue CAGR of 21% through FY25-28. Aiming ₹25,000 crore turnover by FY30.
